Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial

Basit Öğe Kaydı
dc.contributor.authorKomurcu, S.
dc.contributor.authorTurhal, S.
dc.contributor.authorAltundag, K.
dc.contributor.authorAtahan, L.
dc.contributor.authorTurna, H. S.
dc.contributor.authorManavoglu, O.
dc.contributor.authorYavuz, A. A.
dc.contributor.authorOezkoek, S.
dc.contributor.authorAliustaoglu, M.
dc.contributor.authorAltinbas, M.
dc.contributor.authorPak, Y.
dc.contributor.authorCooper, R.
dc.contributor.authorYaylaci, M.
dc.contributor.authorDemirkan, B.
dc.contributor.authorSarihan, S.
dc.contributor.authorOezdemir, F.
dc.date.accessioned2019-10-27T19:37:38Z
dc.date.available2019-10-27T19:37:38Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractWe have performed a prospective evaluation of the efficacy, safety and convenience of the transdermal therapeutic system - fentanyl (TTS-F) in Turkish cancer patients when it was newly available in Turkey. Ninety-nine patients with historically confirmed malignancy and pain entered the study; the mean age was 55.1 (16-58) years. The study duration was 28 days. Transdermal therapeutic system - fentanyl was used in opioid-naive or pre-treated patients. Most patients reported a decrease in pain severity. Use of rescue medication decreased from day 4 to day 28. The majority of patients rated patch convenience of use as excellent. A total of 22.2% of patients experienced adverse events that were either probably related or very likely to be related to the study drug. The majority of the adverse events mentioned were related to the digestive system. Eighteen serious adverse events were reported by 13 patients. Six events were doubtfully related, and 12 events were not related to the study drug. Four patients died during the trial. None of these deaths was attributed to the study drug. In conclusion, the trial showed that TTS-F is easily managed, effective and will help to enable the appropriate opioid administration to patients who are suffering from cancer pain in Turkey.en_US
dc.identifier.doi10.1111/j.1365-2354.2006.00707.xen_US
dc.identifier.endpage73en_US
dc.identifier.issn0961-5423
dc.identifier.issn1365-2354
dc.identifier.issue1en_US
dc.identifier.pmid17227355en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage67en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2354.2006.00707.x
dc.identifier.urihttps://hdl.handle.net/11454/39997
dc.identifier.volume16en_US
dc.identifier.wosWOS:000243403500009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal of Cancer Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecttransdermal fentanylen_US
dc.subjectcancer painen_US
dc.subjectopioidsen_US
dc.titleSafety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu